Generic drugs: Quality, efficacy, safety and Interchangeability;Generika: Qualität, wirksamkeit, sicherheit und austauschbarkeit

Wiener Klinische Wochenschrift

Volumn 120, Issue 3-4, 2008, Pages 63-69

  Tschabitscher, Doris ^a   Platzer, Peter ^a   Baumgärtel, Christoph ^a   Müllner, Marcus ^a  

^a AUSTRIAN AGENCY FOR HEALTH AND FOOD SAFETY   (Austria)

Author keywords

Bioequivalence; Generic drugs; Interchangeability; Marketing authorisation; Pharmaceutical quality

Indexed keywords

GENERIC DRUG;

BIOEQUIVALENCE; DRUG EFFICACY; DRUG LEGISLATION; DRUG MARKETING; DRUG QUALITY; DRUG SAFETY; EUROPEAN UNION; PHARMACEUTICAL CARE; REVIEW; RISK BENEFIT ANALYSIS;

ADOLESCENT; ADULT; ATTITUDE OF HEALTH PERSONNEL; AUSTRIA; COST CONTROL; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG APPROVAL; DRUG COSTS; DRUG TOXICITY; DRUGS, GENERIC; EUROPEAN UNION; FEMALE; HUMANS; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 40549094670     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-008-0927-3     Document Type: Review

References (19)

1. Woolston C (2005) History of Generic Drugs. www.healthresources.caremark. com/topic/printview (Zugriff 14.1.2007)
2. Aspirin Timeline Great Moments in Aspirin's History (2006) Aetna, InteliHealth, Information provided by Harvard Medical School. www.intelihealth.com/IH/ihtIH/WSIHW000/8059/23707/237089.html?d=dmtContent (Zugriff 14.1.2007)
3. Richtlinie 2004/27/EG des Europäischen Parlaments und des Rates zur Änderung der Richtlinie 2001/83/EG zur Schaffung eines Gemeinschaftskodexes für Humanarzneimittel (31. März 2004)
4. European Generic Medicines Association (2004) Data exclusivity. www.egagenerics.com/gen-dataex.htm (Zugriff 28.3.2007)
5. Bundesgesetz vom 2. März 1983 über die Herstellung und das Inverkehrbringen von Arzneimitteln (Arzneimittelgesetz) StF: BGBl. Nr. 185/1983 Änderung BGBl. I Nr. 153/2005
6. Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency
7. Eudralex Volume 2B - Notice to Applicants (Juni 2006) http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol-2/b/ctd_06-2006.pdf (Zugriff 25.5.2007)
8. International Conference on Harmonisation (ICH) of Technical Requirements for registration of Pharmaceuticals for Human Use (Oktober 2006) Leitlinie Q3A (R2) www.ich.org/LOB/media/MEDIA422.pdf (Zugriff 25.5.2007)
9. International Conference on Harmonisation (ICH) of Technical Requirements for registration of Pharmaceuticals for Human Use (June 2006) Leitlinie Q3B(R2) www.ich.org/LOB/media/MEDIA421.pdf (Zugriff 25.5.2007)
10. The European Agency for the Evaluation of Medicinal Products CPMP/EWP/QWP/1401/98 (26. July 2001) Note for guidance on the investigation of bioavailability and bioequivalence
11. Wunderer H (2000) Arzneimittel richtig einnehmen. Wechselwirkungen zwischen Medikamenten und Nahrung, 2. Aufl. Govi-Verlag Pharmazeutischer Verlag GmbH, Eschborn
12. American Medical Association, Featrured Report: Generic Drugs (A-02), June 2002 Ama Annual Meeting. www.ama-assn.org, (Zugriff 11.3.2007)
13. Henney JE (1999) Review of generic bioequivalence studies from the food and drug administration. JAMA 282: 1995
14. Petersen K-U (2003) Generika in der rheumatologischen Pharmakotherapie. Akt Rheumatol 28: 138-143
15. Thirstrup S (2007) Are the requirements in the bioequivalence guidelines strict enough to ascertain interchangeability with narrow therapeutic index drugs? Speech 19th Annual DIA Euro Meeting
16. Ad hoc-Kommission der Deutschen Gesellschaft für Epileptologie (2005) Generika in der Epilepsietherapie: Was ist zu beachten? Akt Neurol 32: 275-278
17. Mayer T, May TW, Altenmüller DM, Sandmann M, Wolf P (1999) Clinical problems with generic antiepileptic drugs. Clin Drug Invest 18 (1): 17-26
18. Electronic Orange Book Approved Drug Products with Therapeutic Equivalence Evaluations Current through April 2007. www.fda.gov/cder/ob/default. htm (Zugriff 20.5.2007)
19. Laegemiddel Danish Medicines Agency (2006) Bioequivalence and labelling of medicinal products with regard to generic substitution. www.dkma.dk Zugriff 20.05.2007